UNLABELLED: Hepatic innate immune cells, in particular, interstitial dendritic cells (DCs), regulate inflammatory responses and may promote inherent liver tolerogenicity. After tissue injury, adenosine triphosphate (ATP) is released and acts as a damage-associated molecular pattern that activates innate immune cells by pattern recognition receptors. CD39 (ectonucleoside triphosphate diphosphohydrolase-1) rapidly hydrolyzes extracellular ATP to maintain physiological levels. We hypothesized that CD39 expression on liver DCs might contribute to regulation of their innate immune functions. Mouse liver conventional myeloid DCs (mDCs) were hyporesponsive to ATP, compared with their splenic counterparts. This disparity was ascribed to more efficient hydrolysis of ATP by higher expression of CD39 on liver mDCs. Human liver mDCs expressed greater levels of CD39 than those from peripheral blood. The comparatively high expression of CD39 on liver mDCs correlated strongly with both ATP hydrolysis and adenosine production. Notably, CD39(-/-) mouse liver mDCs exhibited a more mature phenotype, greater responsiveness to Toll-like receptor 4 ligation, and stronger proinflammatory and immunostimulatory activity than wild-type (WT) liver mDCs. To investigate the role of CD39 on liver mDCs in vivo, we performed orthotopic liver transplantation with extended cold preservation using CD39(-/-) or WT donor mouse livers. Compared to WT liver grafts, CD39(-/-) grafts exhibited enhanced interstitial DC activation, elevated proinflammatory cytokine levels, and more-severe tissue injury. Moreover, portal venous delivery of WT, but not CD39(-/-) liver mDCs, to donor livers immediately post-transplant exerted a protective effect against graft injury in CD39(-/-) to CD39(-/-) liver transplantation. CONCLUSIONS: These data reveal that CD39 expression on conventional liver mDCs limits their proinflammatory activity and confers protective properties on these important innate immune cells against liver transplant ischemia/reperfusion injury.
UNLABELLED: Hepatic innate immune cells, in particular, interstitial dendritic cells (DCs), regulate inflammatory responses and may promote inherent liver tolerogenicity. After tissue injury, adenosine triphosphate (ATP) is released and acts as a damage-associated molecular pattern that activates innate immune cells by pattern recognition receptors. CD39 (ectonucleoside triphosphate diphosphohydrolase-1) rapidly hydrolyzes extracellular ATP to maintain physiological levels. We hypothesized that CD39 expression on liver DCs might contribute to regulation of their innate immune functions. Mouse liver conventional myeloid DCs (mDCs) were hyporesponsive to ATP, compared with their splenic counterparts. This disparity was ascribed to more efficient hydrolysis of ATP by higher expression of CD39 on liver mDCs. Human liver mDCs expressed greater levels of CD39 than those from peripheral blood. The comparatively high expression of CD39 on liver mDCs correlated strongly with both ATP hydrolysis and adenosine production. Notably, CD39(-/-) mouse liver mDCs exhibited a more mature phenotype, greater responsiveness to Toll-like receptor 4 ligation, and stronger proinflammatory and immunostimulatory activity than wild-type (WT) liver mDCs. To investigate the role of CD39 on liver mDCs in vivo, we performed orthotopic liver transplantation with extended cold preservation using CD39(-/-) or WT donormouse livers. Compared to WT liver grafts, CD39(-/-) grafts exhibited enhanced interstitial DC activation, elevated proinflammatory cytokine levels, and more-severe tissue injury. Moreover, portal venous delivery of WT, but not CD39(-/-) liver mDCs, to donor livers immediately post-transplant exerted a protective effect against graft injury in CD39(-/-) to CD39(-/-) liver transplantation. CONCLUSIONS: These data reveal that CD39 expression on conventional liver mDCs limits their proinflammatory activity and confers protective properties on these important innate immune cells against liver transplant ischemia/reperfusion injury.
Authors: Daisuke Tokita; George V Mazariegos; Alan F Zahorchak; Nydia Chien; Masanori Abe; Giorgio Raimondi; Angus W Thomson Journal: Transplantation Date: 2008-02-15 Impact factor: 4.939
Authors: Allan Tsung; Ning Zheng; Geetha Jeyabalan; Kunihiko Izuishi; John R Klune; David A Geller; Michael T Lotze; Lina Lu; Timothy R Billiar Journal: J Leukoc Biol Date: 2006-10-24 Impact factor: 4.962
Authors: C Mutini; S Falzoni; D Ferrari; P Chiozzi; A Morelli; O R Baricordi; G Collo; P Ricciardi-Castagnoli; F Di Virgilio Journal: J Immunol Date: 1999-08-15 Impact factor: 5.422
Authors: Benjamin M Matta; Giorgio Raimondi; Brian R Rosborough; Tina L Sumpter; Angus W Thomson Journal: J Immunol Date: 2012-04-16 Impact factor: 5.422
Authors: Guido Beldi; Yan Wu; Yara Banz; Michael Nowak; Lindsay Miller; Keiichi Enjyoji; Arvand Haschemi; Gennady G Yegutkin; Daniel Candinas; Mark Exley; Simon C Robson Journal: Hepatology Date: 2008-09 Impact factor: 17.425
Authors: Yoshitaka Miyagawa; Pietro Marino; Gianluca Verlengia; Hiroaki Uchida; William F Goins; Shinichiro Yokota; David A Geller; Osamu Yoshida; Joseph Mester; Justus B Cohen; Joseph C Glorioso Journal: Proc Natl Acad Sci U S A Date: 2015-03-16 Impact factor: 11.205
Authors: Anuli C Anyanwu; Yogendra Kanthi; Keigo Fukase; Hui Liao; Tekashi Mimura; Karl C Desch; Martin Gruca; Saabir Kaskar; Hussein Sheikh-Aden; Liguo Chi; Raymond Zhao; Vinita Yadav; Thomas W Wakefield; Matthew C Hyman; David J Pinsky Journal: Arterioscler Thromb Vasc Biol Date: 2019-04 Impact factor: 8.311
Authors: Shinichiro Yokota; Osamu Yoshida; Lei Dou; Anthony V Spadaro; Kumiko Isse; Mark A Ross; Donna B Stolz; Shoko Kimura; Qiang Du; Anthony J Demetris; Angus W Thomson; David A Geller Journal: J Immunol Date: 2015-05-11 Impact factor: 5.422
Authors: O Yoshida; S Kimura; L Dou; B M Matta; S Yokota; M A Ross; D A Geller; A W Thomson Journal: Am J Transplant Date: 2014-06-16 Impact factor: 8.086